Clinical Trials Logo
  1. Home
  2. Transthyretin Amyloidosis
  3. NCT04569903

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Transthyretin Amyloidosis Clinical Trial

Official title:
Evaluation of a Claims-based Algorithm for the Identification of ATTR Amyloidosis in Medical Records

Clinical Trial Summary

The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.

Clinical Trial Description

A screening strategy to identify ATTR in the large background population of patients with one or more common ATTR manifestations, would be of significant clinical value. In addition, novel ATTR therapies have been recently made available or are currently in development in late-stage clinical trials. As early diagnosis and treatment is expected to achieve better outcomes, this makes the development and validation of an easily implemented, rapid and electronically-enabled diagnostic algorithm especially important. A medical and pharmacy claims-based algorithm was developed to potentially identify patients at risk of having ATTR. The goal of this study is to evaluate the ability of the algorithm to identify patients with ATTR by performing diagnostic clinical work up in patients that the algorithm identifies in a large dataset of patients at Yale. The primary objective of this study is to evaluate the diagnostic performance of the algorithm in identifying patients with ATTR amyloidosis. The secondary objective of this study is to estimate the clinical benefit of the algorithm, as measured by the added diagnostic value, i.e. the proportion or rate of patients who were previously undiagnosed. The total obtained prevalence will be assessed and informally compared to the referral-based prevalence of ATTR amyloidosis patients at Yale. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04569903
Study type Interventional
Source Yale University
Contact Cinthia S De Freitas, RN, BSN
Phone (203)785-6315
Email cinthia.defreitas@yale.edu
Status Not yet recruiting
Phase N/A
Start date April 2024
Completion date February 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT03190577 - Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology N/A
Completed NCT03588468 - Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study N/A
Completed NCT03591757 - Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) Early Phase 1
Completed NCT05075798 - Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Terminated NCT04611204 - Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
Recruiting NCT03352089 - Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis N/A
Recruiting NCT05814380 - The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
Completed NCT03923920 - Screening for Systemic Amyloidosis Via the Ligamentum Flavum
Completed NCT03886155 - Cardiac Amyloidosis Screening at Trigger Finger Release
Completed NCT03862807 - Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant Phase 3
Completed NCT02792790 - Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
Completed NCT03860935 - Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Recruiting NCT04963985 - The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients Phase 4
Recruiting NCT05409833 - Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population
Recruiting NCT05635045 - Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR Phase 2
Completed NCT01171859 - Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis Phase 2
Recruiting NCT03237494 - TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT06345235 - New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis